Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial.
作者： A. Radhakrishnan , J.D. Bitran , D.T. Milton , K. Tolzien , S. Hallmeyer
DOI: 10.1179/JOC.2009.21.4.439
关键词:
摘要: AbstractWe sought to evaluate the safety and efficacy of docetaxel oxaliplatin combination as first-line therapy for patients with stage IV or wet IIIB non small cell lung cancer. Patients received at 85 mg/m2 intravenously over 2 hours on days 1 15 along 30 8; both given every 28 days. Cycles were repeated 4 weeks a maximum 6. Fifteen enrolled an overall response rate 50% (95% CI 21-74%). Median progression-free survival was 2.4 months 1-year progression free 10%. 7.9 49% alive year. Most common toxicities nausea, vomiting, dehydration. This has notable activity in advanced non-small cancer favorable toxicity profile.
sci-hub.se 参考文章(23)
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M. J. Thun, Cancer statistics, 2008. CA: A Cancer Journal for Clinicians. ,vol. 58, pp. 71- 96 ,(2008) , 10.3322/CA.2007.0010
Giorgio V Scagliotti, Adjuvant Lung Cancer Project Italy/European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group, The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non-Small Lung Cancer Clinical Cancer Research. ,vol. 11, pp. 5011s- 5016s ,(2005) , 10.1158/1078-0432.CCR-05-9009
F Cappuzzo, S Novello, F De Marinis, V Franciosi, M Maur, A Ceribelli, V Lorusso, F Barbieri, L Castaldini, E Crucitta, L Marini, S Bartolini, G V Scagliotti, L Crinò, Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer British Journal of Cancer. ,vol. 93, pp. 29- 34 ,(2005) , 10.1038/SJ.BJC.6602667
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Goksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David Gandara, Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 26, pp. 3543- 3551 ,(2008) , 10.1200/JCO.2007.15.0375
SG Spiro, RM Rudd, RL Souhami, J Brown, DJ Fairlamb, NH Gower, L Maslove, R Milroy, V Napp, MKB Parmar, MD Peake, RJ Stephens, H Thorpe, DA Waller, P West, Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. ,vol. 59, pp. 828- 836 ,(2004) , 10.1136/THX.2003.020164
A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, D. Bisset, R. Rosell, Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis Journal of the National Cancer Institute. ,vol. 99, pp. 847- 857 ,(2007) , 10.1093/JNCI/DJK196
Stylianos Kakolyris, Nikolaos Ziras, Lambros Vamvakas, John Varthalitis, Pavlos Papakotoulas, Kostas Syrigos, Nikolaos Vardakis, Antonia Kalykaki, Kiriakos Amarantidis, Vassilis Georgoulias, None, Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer. ,vol. 54, pp. 347- 352 ,(2006) , 10.1016/J.LUNGCAN.2006.09.001
Anand Rajeswaran, Andreas Trojan, Bernard Burnand, Massimo Giannelli, Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials Lung Cancer. ,vol. 59, pp. 1- 11 ,(2008) , 10.1016/J.LUNGCAN.2007.07.012
Vittorio Franciosi, Roberto Barbieri, Enrico Aitini, Giovanna Vasini, Gian Carlo Cacciani, Roberto Capra, Roberta Camisa, Stefano Cascinu, Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer. ,vol. 41, pp. 101- 106 ,(2003) , 10.1016/S0169-5002(03)00150-8